The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End

(2016) Amanda R. Wasylishen et al.   Cold Spring Harbor Perspectives in Medicine

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

(2015) Giovanni Ciriello et al.   CELL

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

(2015) Jiajun Zhu et al.   NATURE

MDMX exerts its oncogenic activity via suppression of retinoblastoma protein

(2015) H Zhang et al.   ONCOGENE

UXT, a novel MDMX-binding protein, promotes glycolysis by mitigating p53-mediated restriction of NF-κB activity

(2015) Min Qi et al.   Oncotarget

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer Risk

(2014) Christine M. Eischen et al.   HUMAN MUTATION

Mdmx promotes genomic instability independent of p53 and Mdm2

(2014) A M Carrillo et al.   ONCOGENE

Pla2g16 phospholipase mediates gain-of-function activities of mutant p53

(2014) S. Xiong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity

(2013) V. Pant et al.   GENES & DEVELOPMENT

Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway

(2012) William A. Freed-Pastor et al.   CELL

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

(2011) D. Garcia et al.   GENES & DEVELOPMENT

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

(2011) V. Pant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

(2011) L. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development

(2010) Sean M. Post et al.   CANCER CELL

Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4

(2010) S. Xiong et al.   CANCER RESEARCH

14-3-3γ Inhibition of MDMX-mediated p21 Turnover Independent of p53

(2010) Jun-Ho Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis

(2009) Maddalena Adorno et al.   CELL

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT